Comparison of a Gastroprotective Agent and H2-Receptor Antagonist on Preventative and Therapeutic Effects against Gastroduodenal Mucosal Damage in Patients Taking Low-Dose Aspirin: A prospective, randomized, multicenter, controlled trial - Comparison of a Gastroprotective Agent and H2-Receptor Antagonist on Preventative and Therapeutic Effects against Gastroduodenal Mucosal Damage in Patients Taking Low-Dose Aspirin

Osaka Medical College0 个研究点目标入组 100 人开始时间: 2013年9月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with peptic ulcer; 2) Patients who had undergone gastrectomy or vagotomy; 3) Patients treated with an H2RA or PPI within the 28 days (four weeks) before the start of study medication administration; 4) Patients treated with a non-steroidal anti-inflammatory drug (NSAID) within 28 days (four weeks) before the start of study medication administration; 5) Patients whose corticosteroid regimen (excluding topical medication) was changed (including the dosage and administration) within 14 days (two weeks) before the start of study medication administration; 6) Patients with a serious liver disorder, a serious renal disorder, a serious cardiac disease, and/or a serious blood dyscrasia; 7) Patients who were allergic to or had experienced an adverse reaction to famotidine or teprenone, which scheduled to be administered; 8) Pregnant or lactating women, or women who might become or intended to become pregnant during the study period; 9) Patients determined by an investigator or a sub-investigator to be ineligible.

发起方